Alteogen Inc
KOSDAQ:196170
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
299 000
559 000
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Alteogen Inc
Other Receivables
Alteogen Inc
Other Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Alteogen Inc
KOSDAQ:196170
|
Other Receivables
â‚©1.3B
|
CAGR 3-Years
4%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Other Receivables
â‚©51.8B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
67%
|
CAGR 10-Years
2%
|
|
|
V
|
Voronoi Inc
KOSDAQ:310210
|
Other Receivables
â‚©167.9m
|
CAGR 3-Years
283%
|
CAGR 5-Years
67%
|
CAGR 10-Years
N/A
|
|
|
P
|
PharmaResearch Co Ltd
KOSDAQ:214450
|
Other Receivables
â‚©14.4B
|
CAGR 3-Years
83%
|
CAGR 5-Years
56%
|
CAGR 10-Years
49%
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Other Receivables
â‚©335.4m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
D
|
DND PharmaTech Inc
KOSDAQ:347850
|
Other Receivables
â‚©2.6B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Alteogen Inc
Glance View
In the bustling hub of South Korea's biotech industry, Alteogen Inc. has carved out a distinctive niche with its innovative approach to drug development. Founded in 2008, this company has harnessed the power of advanced biotechnology to specialize in the development of biopharmaceuticals, particularly focusing on creating long-acting protein therapeutics and biobetters. Alteogen's flagship technology, ALT-P7, a proprietary platform for producing antibody-drug conjugates, exemplifies how the company blends scientific ingenuity with commercial acumen. By reimagining existing biological drugs known as biobetters, Alteogen leverages its proprietary technologies to improve the efficacy and delivery of these treatments, promising enhanced convenience and therapeutic outcomes for patients. Financially, Alteogen thrives through both strategic partnerships and its own product pipeline. The company secures revenue by licensing its technology platforms to global pharmaceutical giants, thereby earning milestone payments and royalties. Additionally, Alteogen's ongoing research and development efforts continuously expand its portfolio, particularly in biosimilars—biological products highly similar to already-approved reference products. This dual-pronged approach, combining its proprietary biotechnological innovations with robust strategic alliances, positions Alteogen not just as a player but as an innovator in the biopharmaceutical sector, with the potential for significant impact in the realm of chronic disease treatment.
See Also
What is Alteogen Inc's Other Receivables?
Other Receivables
1.3B
KRW
Based on the financial report for Jun 30, 2025, Alteogen Inc's Other Receivables amounts to 1.3B KRW.
What is Alteogen Inc's Other Receivables growth rate?
Other Receivables CAGR 5Y
14%
Over the last year, the Other Receivables growth was 6%. The average annual Other Receivables growth rates for Alteogen Inc have been 4% over the past three years , 14% over the past five years .